Continental Advisors LLC Gilead Sciences, Inc. Transaction History

Continental Advisors LLC

$248 Million
Q1 2024

A detailed history of Continental Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Continental Advisors LLC holds 22,000 shares of GILD stock, worth $1.47 Million. This represents 0.65% of its overall portfolio holdings.

Number of Shares

22,000

Previous 74,903 70.63%

Holding current value

$1.47 Million

Previous $6.07 Million 73.45%

% of portfolio

0.65%

Previous 2.37%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $787,380 - $960,190	-11,000 Reduced 14.69%	63,903 $4.68 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $512,890 - $581,630	-7,000 Reduced 8.55%	74,903 $6.07 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $1.25 Million - $1.43 Million	-16,500 Reduced 16.77%	81,903 $6.31 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $1.93 Million - $2.2 Million	25,000 Added 34.06%	98,403 $8.16 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $656,478 - $942,476	-10,534 Reduced 12.55%	73,403 $6.3 Million

Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $238,160 - $272,040	-4,000 Reduced 4.55%	83,937 $5.18 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $173,760 - $217,740	3,000 Added 3.53%	87,937 $5.23 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $973,199 - $1.1 Million	-15,000 Reduced 15.01%	84,937 $6.17 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $1.62 Million - $1.75 Million	-24,000 Reduced 19.36%	99,937 $6.98 Million
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $190,410 - $208,049	-3,000 Reduced 2.36%	123,937 $8.53 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $2.25 Million - $2.57 Million	37,500 Added 41.93%	126,937 $8.2 Million
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $1.64 Million - $1.87 Million	29,000 Added 47.98%	89,437 $5.21 Million
Q3 2020 Nov 16, 2020	BUY	$62.1 - $78.08 $1.12 Million - $1.41 Million	18,000 Added 42.42%	60,437 $3.82 Million
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $361,700 - $420,000	5,000 Added 13.36%	42,437 $3.27 Million
Q1 2020 May 08, 2020	BUY	$62.63 - $80.22 $626,300 - $802,200	10,000 Added 36.45%	37,437 $2.8 Million
Q4 2019 Feb 10, 2020	SELL	$61.62 - $67.78 $208,953 - $229,841	-3,391 Reduced 11.0%	27,437 $1.78 Million
Q1 2019 May 14, 2019	SELL	$62.53 - $70.05 $1.68 Million - $1.88 Million	-26,872 Reduced 46.57%	30,828 $2 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $691,416 - $765,524	-9,700 Reduced 14.39%	57,700 $4.46 Million
Q2 2018 Aug 13, 2018	BUY	$64.88 - $75.68 $966,711 - $1.13 Million	14,900 Added 28.38%	67,400 $4.78 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $3.79 Million - $4.49 Million	52,500	52,500 $4.25 Million

Others Institutions Holding GILD

# of Institutions

1,885

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $83.6B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Continental Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Continental Advisors LLC with notifications on news.

Account

Continental Advisors LLC Gilead Sciences, Inc. Transaction History